HomeCompareAPDN vs ARCC

APDN vs ARCC: Dividend Comparison 2026

APDN yields 35.59% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APDN wins by $157.2K in total portfolio value
10 years
APDN
APDN
● Live price
35.59%
Share price
$5.62
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$181.8K
Annual income
$27,846.09
Full APDN calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — APDN vs ARCC

📍 APDN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPDNARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APDN + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APDN pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APDN
Annual income on $10K today (after 15% tax)
$3,024.91/yr
After 10yr DRIP, annual income (after tax)
$23,669.18/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, APDN beats the other by $23,668.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APDN + ARCC for your $10,000?

APDN: 50%ARCC: 50%
100% ARCC50/50100% APDN
Portfolio after 10yr
$103.2K
Annual income
$13,923.62/yr
Blended yield
13.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

APDN
Analyst Ratings
3
Buy
1
Sell
Consensus: Buy
Price Target
$1.50
-73.3% upside vs current
Range: $1.50 — $1.50
Altman Z
-29.8
Piotroski
2/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APDN buys
0
ARCC buys
0
No recent congressional trades found for APDN or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPDNARCC
Forward yield35.59%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$181.8K$24.5K
Annual income after 10y$27,846.09$1.16
Total dividends collected$131.9K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$1.50$21.88

Year-by-year: APDN vs ARCC ($10,000, DRIP)

YearAPDN PortfolioAPDN Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$14,259$3,558.72$11,381$541.15+$2.9KAPDN
2$19,999$4,742.32$12,621$284.08+$7.4KAPDN
3$27,615$6,216.38$13,827$145.31+$13.8KAPDN
4$37,571$8,022.22$15,062$73.43+$22.5KAPDN
5$50,401$10,200.20$16,364$36.89+$34.0KAPDN
6$66,717$12,788.31$17,757$18.49+$49.0KAPDN
7$87,208$15,820.84$19,258$9.25+$68.0KAPDN
8$112,640$19,327.04$20,880$4.63+$91.8KAPDN
9$143,855$23,330.07$22,636$2.32+$121.2KAPDN
10$181,771$27,846.09$24,539$1.16+$157.2KAPDN

APDN vs ARCC: Complete Analysis 2026

APDNStock

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Full APDN Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this APDN vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APDN vs SCHDAPDN vs JEPIAPDN vs OAPDN vs KOAPDN vs MAINAPDN vs HTGCAPDN vs GBDCAPDN vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.